Eficacia y efectos adversos tras iniciar terapia combinada de metotrexate + etanercept en pacientes con artritis reumatoide atendidos en el Hospital Naval Guayaquil en el periodo 2015 - 2020.

Abstract

Background: rheumatoid arthritis is one of the autoimmune diseases that most people suffer today, especially women over 50 years of age, its etiology is unknown, although it can be generated by a series of Both genetic and environmental factors, with respect to its management, the aim is to avoid its progression by establishing a treatment in the initial stages through the use of biological drugs plus a DMARD, ensuring that it is effective and that it generates fewer adverse effects. Objective: To demonstrate the efficacy and adverse effects after starting Methotrexate + Etanercept combination therapy in patients with Rheumatoid Arthritis. Materials and methods: The research carried out was based on an observational, retrospective, analytical cross-sectional study, using the medical records of the patients of the ASIS system of the Hospital Naval Guayaquil, the search at the beginning gave us a total of 1,337 patients classified with diagnosis of Rheumatoid Arthritis, among which our sample was reduced to only 71 patients who met the inclusion criteria.Results: Through this study it was found that RA appeared more frequently in female persons (84.51%), the most representative age was 70-79 years (29.58%); Among the most frequent types of adverse effects we find: elevation of liver enzymes (15.49%), hematological alterations (11.27%) and gastrointestinal alterations (8.45%). The effectiveness of the treatment in a period of 6 months was presented with a Chi2 = 0.04 favoring those patients who maintain therapy for longer than 6 months. Conclusion: The use of the combined therapy of Methotrexate + Etanercept if it manages to slow down the course of Arthritis Keeping it under control, although certain adverse effects occur in patients, but it should be emphasized that the benefit outweighs much more, therefore it is advisable to help the patient to control these secondary discomfort after use by sending symptomatic treatment.